Biotracker™ Software Application Achieves GeneChip-Compatible™ Status
News Sep 14, 2005
Ocimum Biosolutions has announced that its Biotracker™ software application has achieved GeneChip-compatible™ status with the Affymetrix Inc. GeneChip® microarray platform and that it has agreed to participate in the Affymetrix GeneChip-compatible™ Applications Program, which is designed to provide customers with a broad spectrum of software solutions for biomedical research and development.
As a GeneChip-compatible™ software provider, Ocimum is committed to seamlessly integrating its Biotracker™ with the Affymetrix GeneChip platform.
Ocimum's Biotracker™ is a GLP and US FDA 21 CFR Part 11 compliant Laboratory Information and Knowledge Management System.
It is a tool for improving laboratory performance which is designed to allow analysts to keep track of samples, reagents, instruments, processes, and results at every stage of a project.
Biotracker™ is a customized LIMS solution which has various modules, some of which are: Laboratory Administration module, Resource Schedule module, Project Tracking, Analysis and Result Archival module, Inventory Management and Tracking System module, Sample Tracking module & Plate tracking module.
“We are very happy to be part of the GeneChip-compatible™ Applications Program with the market leader in the microarray space,” said Ms. Anuradha Acharya, C.E.O., Ocimum Biosolutions.
“Biotracker™ is a very flexible and configurable program and we understand the Affymetrix platform well to provide users with customized solutions.”
“Many of our customers are now applying microarray methods initially developed for basic research into translational medicine and clinical research,” said Steve Lincoln, vice president of Informatics at Affymetrix.
“We are pleased to be engaged with leading software providers, including Ocimum Biosolutions, in developing integrated solutions to address these emerging needs.”
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.